SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* Llewelyn Linda (Last) (First) (Middle) C/O HEALTH CATALYST, INC. 3165 MILLROCK DRIVE, #400 (Street) SALT LAKE CITY UT 84121 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol Health Catalyst, Inc. [ HCAT ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Chief People Officer
	3. Date of Earliest Transaction (Month/Day/Year) 12/18/2020
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/18/2020		M		1,500	A	$10.6	23,418	D
Common Stock	12/18/2020		M		1,000	A	$10.04	24,418	D
Common Stock	12/18/2020		M		260	A	$4.42	24,678	D
Common Stock	12/18/2020		M		500	A	$6.24	25,178	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$10.6	12/18/2020		M			1,500	10/14/2020(1)	10/14/2026	Common Stock	1,500	$0.00	2,250	D
Stock Option (Right to Buy)	$10.04	12/18/2020		M			1,000	06/01/2019(2)	08/04/2025	Common Stock	1,000	$0.00	0.00	D
Stock Option (Right to Buy)	$6.24	12/18/2020		M			500	05/13/2018(3)	05/13/2024	Common Stock	500	$0.00	0.00	D
Stock Option (Right to Buy)	$4.42	12/18/2020		M			260	06/17/2017(4)	08/28/2023	Common Stock	260	$0.00	0.00	D

Explanation of Responses:

1. 25% of the 3,750 shares underlying the options vested in an annual installment on October 14, 2017 and the remaining balance vested in equal monthly installments until the option vested in full on October 14, 2020.

2. 25% of the 1000 shares underlying the options vested in an annual installment on June 1, 2016 and the remaining balance vested in equal monthly installments until the option vested in full on June 1, 2019.

3. 25% of the 500 shares underlying the options vested in an annual installment on May 13, 2015 and the remaining balance vested in equal monthly installments until the option vested in full on May 13, 2018.

4. 25% of the 1,250 shares underlying the options vested in an annual installment on June 17, 2014 and the remaining balance vested in equal monthly installments until the option vested in full on June 17, 2017.

Remarks:

	/s/ Daniel Orenstein, as Attorney-in-Fact	12/21/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.